340 related articles for article (PubMed ID: 29893227)
1. Clinical management of psoriatic arthritis.
Van den Bosch F; Coates L
Lancet; 2018 Jun; 391(10136):2285-2294. PubMed ID: 29893227
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatment Concepts in Psoriatic Arthritis.
Boyd T; Kavanaugh A
Rheum Dis Clin North Am; 2015 Nov; 41(4):739-54. PubMed ID: 26476230
[TBL] [Abstract][Full Text] [Related]
3. Management of psoriatic arthritis among cutaneous psoriasis patients: from pathogenesis to therapy.
Hoelt P; Confavreux C; Jullien D; Villani AP
G Ital Dermatol Venereol; 2017 Oct; 152(5):458-473. PubMed ID: 28534601
[TBL] [Abstract][Full Text] [Related]
4. Early psoriatic arthritis.
Gladman DD
Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
[TBL] [Abstract][Full Text] [Related]
5. Clinical remission in rheumatoid arthritis and psoriatic arthritis.
Lubrano E; Mesina F; Caporali R
Clin Exp Rheumatol; 2018; 36(5):900-910. PubMed ID: 29600949
[TBL] [Abstract][Full Text] [Related]
6. Difficult to treat psoriatic arthritis - how should we manage?
Kumthekar A; Ashrafi M; Deodhar A
Clin Rheumatol; 2023 Sep; 42(9):2251-2265. PubMed ID: 37097525
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of psoriatic arthritis.
Balakrishnan C; Madnani N
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
[TBL] [Abstract][Full Text] [Related]
8. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
9. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
10. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
11. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
12. Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?
Mulder MLM; den Broeder AA; van Ginneken BTJ; Mahler EAM; van den Hoogen FHJ; Vriezekolk JE; Wenink MH
Rheumatology (Oxford); 2019 Dec; 58(12):2330-2331. PubMed ID: 31230083
[No Abstract] [Full Text] [Related]
13. New drugs for peripheral joint psoriatic arthritis.
Drug Ther Bull; 2006 Jan; 44(1):1-5. PubMed ID: 16425898
[TBL] [Abstract][Full Text] [Related]
14. Psoriatic rheumatism. Inflammatory arthropathy.
Macovei L; Brujbu I
Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):45-51. PubMed ID: 24741774
[TBL] [Abstract][Full Text] [Related]
15. Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.
van Mens LJJ; van de Sande MGH; Fluri IA; Atiqi S; van Kuijk AWR; Baeten DLP
Arthritis Res Ther; 2017 Oct; 19(1):226. PubMed ID: 29017591
[TBL] [Abstract][Full Text] [Related]
16. [Psoriatic arthritis: important aspects for the dermatological practice].
Boehncke WH
Hautarzt; 2021 Nov; 72(11):946-952. PubMed ID: 34591123
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for psoriatic arthritis.
Schemoul J; Poulain C; Claudepierre P
Joint Bone Spine; 2018 Oct; 85(5):537-544. PubMed ID: 29155104
[TBL] [Abstract][Full Text] [Related]
18. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
19. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
Torre Alonso JC; Díaz Del Campo Fontecha P; Almodóvar R; Cañete JD; Montilla Morales C; Moreno M; Plasencia-Rodríguez C; Ramírez García J; Queiro R
Reumatol Clin (Engl Ed); 2018; 14(5):254-268. PubMed ID: 29111261
[TBL] [Abstract][Full Text] [Related]
20. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.
D'Angiolella LS; Cortesi PA; Lafranconi A; Micale M; Mangano S; Cesana G; Mantovani LG
Pharmacoeconomics; 2018 May; 36(5):567-589. PubMed ID: 29441473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
